In Face of Multiple Patent Cliffs, Novartis' Prostate Cancer Drug Shows Promise

In Face of Multiple Patent Cliffs, Novartis' Prostate Cancer Drug Shows Promise

Submitted by admin on December 5, 2022 - 10:58am
Source: 
BioSpace
News Tags: 
Novartis
prostate cancer
Pluvicto
clinical trials
patents
patent cliff
Headline: 
In Face of Multiple Patent Cliffs, Novartis' Prostate Cancer Drug Shows Promise
snippet: 

With Novartis facing a potential loss of $9 billion through 2026 from patent expirations, the company announced topline results for Pluvicto for PSMA-positive metastatic castration-resistant prostate cancer (mCRPC).

Do Not Allow Advertisers to Use My Personal information